NO20034453L - Anvendelse av CD25-bindende molekyler i steroid-resistente pasienter - Google Patents
Anvendelse av CD25-bindende molekyler i steroid-resistente pasienterInfo
- Publication number
- NO20034453L NO20034453L NO20034453A NO20034453A NO20034453L NO 20034453 L NO20034453 L NO 20034453L NO 20034453 A NO20034453 A NO 20034453A NO 20034453 A NO20034453 A NO 20034453A NO 20034453 L NO20034453 L NO 20034453L
- Authority
- NO
- Norway
- Prior art keywords
- steroid
- binding molecules
- resistant patients
- resistant
- patient
- Prior art date
Links
- 150000003431 steroids Chemical class 0.000 title abstract 3
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 title abstract 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 title abstract 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 title abstract 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 201000004624 Dermatitis Diseases 0.000 abstract 1
- 208000007465 Giant cell arteritis Diseases 0.000 abstract 1
- 206010047115 Vasculitis Diseases 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 201000000306 sarcoidosis Diseases 0.000 abstract 1
- 206010043207 temporal arteritis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0108817A GB0108817D0 (en) | 2001-04-06 | 2001-04-06 | Therapy |
GB0108821A GB0108821D0 (en) | 2001-04-06 | 2001-04-06 | Therapy |
GB0108816A GB0108816D0 (en) | 2001-04-06 | 2001-04-06 | Therapy |
PCT/EP2002/003808 WO2002081508A2 (en) | 2001-04-06 | 2002-04-05 | Use of cd25 binding molecules in steroid-resistant patients |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20034453D0 NO20034453D0 (no) | 2003-10-03 |
NO20034453L true NO20034453L (no) | 2003-12-04 |
Family
ID=27256143
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20034453A NO20034453L (no) | 2001-04-06 | 2003-10-03 | Anvendelse av CD25-bindende molekyler i steroid-resistente pasienter |
Country Status (21)
Country | Link |
---|---|
US (2) | US20040146508A1 (no) |
EP (2) | EP1379557B1 (no) |
JP (2) | JP2005502593A (no) |
KR (2) | KR100975042B1 (no) |
CN (1) | CN1296386C (no) |
AT (1) | ATE408629T1 (no) |
AU (1) | AU2002315271B2 (no) |
BR (1) | BR0208656A (no) |
CA (1) | CA2443405A1 (no) |
CZ (1) | CZ20032672A3 (no) |
DE (1) | DE60228945D1 (no) |
ES (1) | ES2314067T3 (no) |
HU (1) | HUP0400986A3 (no) |
IL (2) | IL158060A0 (no) |
MX (1) | MXPA03009115A (no) |
NO (1) | NO20034453L (no) |
NZ (1) | NZ528411A (no) |
PL (1) | PL363029A1 (no) |
PT (1) | PT1379557E (no) |
SK (1) | SK12212003A3 (no) |
WO (1) | WO2002081508A2 (no) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7575742B2 (en) * | 2002-06-28 | 2009-08-18 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating autoimmune diseases with interferon-beta and IL-2R antagonist |
JP2007506681A (ja) * | 2003-09-23 | 2007-03-22 | ピーディーエル バイオファーマ,インコーポレイティド | 抗il−2受容体抗体による呼吸器疾患の治療 |
GB0507696D0 (en) * | 2005-04-15 | 2005-05-25 | Novartis Ag | Organic compounds |
WO2007014420A1 (en) * | 2005-08-02 | 2007-02-08 | Centenary Institute Of Cancer Medicine And Cell Biology | Method for identifying regulatory t cells |
WO2009145831A1 (en) * | 2008-04-02 | 2009-12-03 | Geisinger Clinic | Treatment of the idiopathic nephrotic syndrome spectrum diseases using basiliximab |
TW201834698A (zh) * | 2017-03-03 | 2018-10-01 | 國立研究開發法人國立癌症研究中心 | 抗il-7r抗體之抗體藥物共軛物與處置癌或發炎用之包含抗il-7r抗體與細胞傷害劑之抗體藥物共軛物之醫藥組成物 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2188941B (en) * | 1986-04-14 | 1990-06-06 | Bayer Ag | Monoclonal antibodies recognizing human interleukin-2-receptor |
IL162181A (en) * | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
HUT60768A (en) * | 1990-03-16 | 1992-10-28 | Sandoz Ag | Process for producing cd25 fixing molecules |
EP0631783A1 (en) * | 1993-06-03 | 1995-01-04 | Mitsubishi Chemical Corporation | Antiviral combinations of 2',3'-di-deoxyribonucleosides with 6-benzyl-1-ethoxymethyl-5-substituted uracil derivatives |
US5567590A (en) * | 1994-01-06 | 1996-10-22 | National Jewish Center For Immunology And Respiratory | Methods of diagnosing steroid-resistant inflammation due to type I or type II nuclear glucocorticoid receptor binding abnormalities |
US6013256A (en) * | 1996-09-24 | 2000-01-11 | Protein Design Labs, Inc. | Method of preventing acute rejection following solid organ transplantation |
ES2291040T3 (es) * | 1998-07-27 | 2008-02-16 | Novartis Ag | Uso de basiliximab en el tratamiento de artritis reumatoide o enfermedades de la piel. |
WO2000025816A1 (en) * | 1998-10-30 | 2000-05-11 | The University Of Miami | Treatment of hepatitis c by administration of anti-il-2 receptor monoclonal antibody and an antiviral compound |
GB0007911D0 (en) * | 2000-03-30 | 2000-05-17 | Novartis Ag | Organic compounds |
-
2002
- 2002-04-05 PT PT02740446T patent/PT1379557E/pt unknown
- 2002-04-05 EP EP02740446A patent/EP1379557B1/en not_active Expired - Lifetime
- 2002-04-05 SK SK1221-2003A patent/SK12212003A3/sk unknown
- 2002-04-05 MX MXPA03009115A patent/MXPA03009115A/es active IP Right Grant
- 2002-04-05 IL IL15806002A patent/IL158060A0/xx unknown
- 2002-04-05 CZ CZ20032672A patent/CZ20032672A3/cs unknown
- 2002-04-05 PL PL02363029A patent/PL363029A1/xx not_active Application Discontinuation
- 2002-04-05 JP JP2002579494A patent/JP2005502593A/ja not_active Withdrawn
- 2002-04-05 ES ES02740446T patent/ES2314067T3/es not_active Expired - Lifetime
- 2002-04-05 CN CNB028074807A patent/CN1296386C/zh not_active Expired - Fee Related
- 2002-04-05 CA CA002443405A patent/CA2443405A1/en not_active Abandoned
- 2002-04-05 US US10/474,071 patent/US20040146508A1/en not_active Abandoned
- 2002-04-05 WO PCT/EP2002/003808 patent/WO2002081508A2/en active Application Filing
- 2002-04-05 KR KR1020037012923A patent/KR100975042B1/ko not_active IP Right Cessation
- 2002-04-05 EP EP08016235A patent/EP2058332A1/en not_active Withdrawn
- 2002-04-05 NZ NZ528411A patent/NZ528411A/en not_active IP Right Cessation
- 2002-04-05 HU HU0400986A patent/HUP0400986A3/hu unknown
- 2002-04-05 BR BR0208656-5A patent/BR0208656A/pt not_active Application Discontinuation
- 2002-04-05 KR KR1020087028908A patent/KR20080110687A/ko not_active Application Discontinuation
- 2002-04-05 AT AT02740446T patent/ATE408629T1/de active
- 2002-04-05 DE DE60228945T patent/DE60228945D1/de not_active Expired - Lifetime
- 2002-04-05 AU AU2002315271A patent/AU2002315271B2/en not_active Ceased
-
2003
- 2003-09-22 IL IL158060A patent/IL158060A/en not_active IP Right Cessation
- 2003-10-03 NO NO20034453A patent/NO20034453L/no not_active Application Discontinuation
-
2008
- 2008-12-24 JP JP2008328042A patent/JP2009102367A/ja active Pending
-
2009
- 2009-02-13 US US12/378,454 patent/US20090274691A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2002081508A2 (en) | 2002-10-17 |
JP2009102367A (ja) | 2009-05-14 |
IL158060A0 (en) | 2004-03-28 |
PT1379557E (pt) | 2008-12-29 |
EP1379557A2 (en) | 2004-01-14 |
AU2002315271B2 (en) | 2006-08-03 |
JP2005502593A (ja) | 2005-01-27 |
HUP0400986A3 (en) | 2012-09-28 |
CA2443405A1 (en) | 2002-10-17 |
NO20034453D0 (no) | 2003-10-03 |
SK12212003A3 (sk) | 2004-05-04 |
BR0208656A (pt) | 2004-08-10 |
ES2314067T3 (es) | 2009-03-16 |
US20090274691A1 (en) | 2009-11-05 |
CN1296386C (zh) | 2007-01-24 |
IL158060A (en) | 2009-12-24 |
KR100975042B1 (ko) | 2010-08-11 |
DE60228945D1 (de) | 2008-10-30 |
KR20030088485A (ko) | 2003-11-19 |
PL363029A1 (en) | 2004-11-15 |
EP2058332A1 (en) | 2009-05-13 |
ATE408629T1 (de) | 2008-10-15 |
WO2002081508A3 (en) | 2003-08-28 |
HUP0400986A2 (hu) | 2004-08-30 |
EP1379557B1 (en) | 2008-09-17 |
US20040146508A1 (en) | 2004-07-29 |
CZ20032672A3 (cs) | 2003-12-17 |
KR20080110687A (ko) | 2008-12-18 |
NZ528411A (en) | 2005-04-29 |
MXPA03009115A (es) | 2004-11-22 |
CN1527840A (zh) | 2004-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR13C0021I2 (fr) | Conjugates d'exendin-4 et leur utilisation medicale | |
LV12558A (lv) | Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate | |
BR9911076A (pt) | Uso de peg-ifn-alfa e ribavirina para o tratamento de hepatite c crÈnica | |
CY1111359T1 (el) | Μεμαντινη για την θεραπεια ηπιας εως μετριας ασθενειας alzheimer | |
ATE503490T1 (de) | Monodisperse mischungen und verfahren zur behandlung von diabetes | |
IL225192A (en) | Combinations of dextromethorphan and quinidine for the preparation of mental illness, neuropathic pain or brain injury | |
TW264480B (no) | ||
ATE510562T1 (de) | Anti-ailim antikörper zur behandlung von crohn's | |
WO2003047524A3 (en) | Methods and compositions for modulating the immune system and uses thereof | |
ATE497775T1 (de) | Verwendung einer kombination von cyclosporin und pegylierten interferonen zur behandlung von hepatitis c (hcv) | |
TW200630089A (en) | Treatment methods | |
UA99094C2 (ru) | Способ лечения пациента с системной красной волчанкой | |
NO20081149L (no) | Fremgangsmate for behandling av B-celle-maligniteter ved bruk av TACI-IG fusjonsmolekyl | |
DE60231131D1 (de) | Vakzine und verwendung davon zur behandlung amyotrophischer lateralsklerose | |
KR950700079A (ko) | 이식체-대-숙주 질환을 억제하기 위한 인터루킨-10의 용도(Use of interleukin-10 to suppress graft-vs. -host disease) | |
SE0102147D0 (sv) | New methods | |
NO20034453L (no) | Anvendelse av CD25-bindende molekyler i steroid-resistente pasienter | |
BR9912609A (pt) | Métodos de uso de um análogo de somatostatina | |
PT1237562E (pt) | Processo de preparacao de extractos de micania contendo micanolida e di-hidromicanolida e utilizacao no tratamento das doencas proliferativas | |
EP0948967A3 (en) | Treatment of viral disease in swine | |
WO2003097082A3 (en) | Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies | |
WO2000063386A3 (en) | Prevention, diagnosis and treatment of lyme disease | |
WO2000078800A3 (en) | Combined decorin binding protein and outer surface protein compositions and methods of use | |
TW200501958A (en) | A therapeutic agent for treating a behavioral disorder | |
UA29106A (uk) | Спосіб лікування вібраційної хвороби |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |